Jeff Cehelsky

870 total citations
15 papers, 636 citations indexed

About

Jeff Cehelsky is a scholar working on Molecular Biology, Epidemiology and Surgery. According to data from OpenAlex, Jeff Cehelsky has authored 15 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Epidemiology and 4 papers in Surgery. Recurrent topics in Jeff Cehelsky's work include Respiratory viral infections research (6 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers) and Virus-based gene therapy research (2 papers). Jeff Cehelsky is often cited by papers focused on Respiratory viral infections research (6 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers) and Virus-based gene therapy research (2 papers). Jeff Cehelsky collaborates with scholars based in United States, Germany and Australia. Jeff Cehelsky's co-authors include Akshay Vaishnaw, John P. DeVincenzo, Rene Alvarez, Iva Toudjarska, Sayda M. Elbashir, Jens Harborth, Lubomir V. Nechev, Rachel Meyers, Tom Wilkinson and Saraswathy V. Nochur and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

Jeff Cehelsky

15 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeff Cehelsky United States 8 332 222 157 151 67 15 636
Girija Goyal United States 13 133 0.4× 235 1.1× 89 0.6× 127 0.8× 63 0.9× 22 940
Norbert Riedel United States 9 152 0.5× 316 1.4× 56 0.4× 156 1.0× 42 0.6× 14 911
Natalie W. Fowlkes United States 12 68 0.2× 117 0.5× 73 0.5× 56 0.4× 45 0.7× 57 453
Jade Kurihara United States 13 68 0.2× 112 0.5× 145 0.9× 67 0.4× 37 0.6× 21 494
Laurie T. Krug United States 19 560 1.7× 144 0.6× 115 0.7× 92 0.6× 55 0.8× 51 918
Xudong Guo China 12 80 0.2× 195 0.9× 22 0.1× 89 0.6× 65 1.0× 31 469
Elena Copreni Italy 14 53 0.2× 281 1.3× 375 2.4× 50 0.3× 63 0.9× 27 677
Sun D China 13 86 0.3× 392 1.8× 31 0.2× 87 0.6× 36 0.5× 56 705
Parul Trivedi United States 12 138 0.4× 286 1.3× 20 0.1× 172 1.1× 37 0.6× 19 823
Marina C. Costa Portugal 18 282 0.8× 631 2.8× 60 0.4× 223 1.5× 425 6.3× 49 1.1k

Countries citing papers authored by Jeff Cehelsky

Since Specialization
Citations

This map shows the geographic impact of Jeff Cehelsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeff Cehelsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeff Cehelsky more than expected).

Fields of papers citing papers by Jeff Cehelsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeff Cehelsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeff Cehelsky. The network helps show where Jeff Cehelsky may publish in the future.

Co-authorship network of co-authors of Jeff Cehelsky

This figure shows the co-authorship network connecting the top 25 collaborators of Jeff Cehelsky. A scholar is included among the top collaborators of Jeff Cehelsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeff Cehelsky. Jeff Cehelsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Adams, David, Teresa Coelho, Isabel Conceição, et al.. (2016). Phase 2 Open-Label Extension Study (OLE) of Patisiran, an Investigational RNAi Therapeutic for Familial Amyloid Polyneuropathy (FAP) (S38.003). Neurology. 86(16_supplement). 3 indexed citations
2.
Adams, David, Teresa Coelho, Brian R. Bettencourt, et al.. (2015). Burden of Illness for Patients with familial amyloidotic Polyneuropathy (Fap) Begins Early and Increases with Disease Progression. Value in Health. 18(3). A287–A287. 1 indexed citations
3.
Coelho, Teresa, Ole B. Suhr, Isabel Conceição, et al.. (2015). Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic for the treatment of familial amyloid polyneuropathy (S9.003). Neurology. 84(14_supplement). 5 indexed citations
4.
Kim, Young‐In, John P. DeVincenzo, Bart G. Jones, et al.. (2014). Respiratory Syncytial Virus Human Experimental Infection Model: Provenance, Production, and Sequence of Low-Passaged Memphis-37 Challenge Virus. PLoS ONE. 9(11). e113100–e113100. 31 indexed citations
5.
Adams, David, Teresa Coelho, Ole B. Suhr, et al.. (2013). Interim results from phase ii trial of aln-ttr02, a novel RNAi therapeutic for the treatment of familial amyloidotic polyneuropathy. Journal of the Peripheral Nervous System. 18. 1–2. 2 indexed citations
6.
Simon, Amy, Verena Karsten, Jeff Cehelsky, et al.. (2012). Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients. 40. 1476. 15 indexed citations
7.
Fitzgerald, Kevin, Maria Frank-Kamenetsky, Timothy Mant, et al.. (2012). Abstract 67: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Results for ALN-PCS, a Novel RNAi Therapeutic for the Treatment of Hypercholesterolemia. Arteriosclerosis Thrombosis and Vascular Biology. 32(suppl_1). 7 indexed citations
8.
Sah, Dinah W.Y., Qingmin Chen, Anthony Rossomando, et al.. (2011). ALN-TTR, an RNAI therapeutic for the treatment of transthyretin amyloidosis. Nucleic Acid Therapeutics. 21(5). 1 indexed citations
9.
Cervantes, Andrés, María Alsina, Josep Tabernero, et al.. (2011). Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.. Journal of Clinical Oncology. 29(15_suppl). 3025–3025. 44 indexed citations
10.
DeVincenzo, John P., Tom Wilkinson, Akshay Vaishnaw, et al.. (2010). Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus. American Journal of Respiratory and Critical Care Medicine. 182(10). 1305–1314. 237 indexed citations
11.
Zamora, Martin R., Marie Budev, Mark W. Rolfe, et al.. (2010). 41: Results of a Randomized Phase 2 Trial of ALN-RSV01, an RNAi Therapeutic, Lung Transplant (LTX) Patients Infected with Respiratory Syncytial Virus (RSV). The Journal of Heart and Lung Transplantation. 29(2). S20–S20. 4 indexed citations
12.
Gollob, Jared, J. R. Infante, Geoffrey I. Shapiro, et al.. (2010). Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.. Journal of Clinical Oncology. 28(15_suppl). 3042–3042. 7 indexed citations
13.
DeVincenzo, John P., Jeff Cehelsky, Rene Alvarez, et al.. (2008). Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Research. 77(3). 225–231. 197 indexed citations
14.
DeVincenzo, John P., Rob Lambkin‐Williams, Jeff Cehelsky, et al.. (2008). Development of a Human Experimental Infection Model of Respiratory Syncytial Virus (RSV) and Evaluation of an RNA Interference (RNAi) Therapeutic for Safety and Anti-Viral Efficacy in Man. Journal of Allergy and Clinical Immunology. 121(2). S268–S268. 1 indexed citations
15.
Warren, Katherine E., Regina I. Jakacki, Brigitte C. Widemann, et al.. (2006). Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group. Cancer Chemotherapy and Pharmacology. 58(3). 343–347. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Girija Goyal Breakdown of academic impact, for papers by Norbert Riedel Breakdown of academic impact, for papers by Natalie W. Fowlkes Breakdown of academic impact, for papers by Jade Kurihara Breakdown of academic impact, for papers by Laurie T. Krug Breakdown of academic impact, for papers by Xudong Guo Breakdown of academic impact, for papers by Elena Copreni Breakdown of academic impact, for papers by Sun D Breakdown of academic impact, for papers by Parul Trivedi Breakdown of academic impact, for papers by Marina C. Costa
Rankless by CCL
2026